Navigation Links
Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
Date:11/13/2012

WASHINGTON, Nov. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 24-week results from the continuation of an ongoing Phase IIb study of baricitinib, an orally available janus kinase (JAK) inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to treatment with methotrexate. Additionally, Magnetic Resonance Imaging (MRI) technology was used in a sub-study to examine the effect of baricitinib on joint erosion and other markers of structural changes in and around the joint. The findings were presented at the annual meeting of the American College of Rheumatology (ACR) in Washington, D.C.

Positive results of the placebo-controlled 12-week portion of the study were presented at the European League Against Rheumatism's (EULAR) Annual European Congress of Rheumatology in June 2012.[1] Patients taking baricitinib 4 mg or 8 mg once daily reported significant differences in ACR20, ACR50 and ACR70 responses compared with patients taking placebo. Data from the 12- to 24-week portion of the study, which did not include a placebo control, showed that patients who continued to receive 2 mg, 4 mg or 8 mg baricitinib once daily doses maintained or improved ACR20, ACR50 and ACR70 responses. The following chart defines the percentage of patients that achieved ACR20, ACR50 and ACR70 at 24 weeks of treatment with baricitinib.Response at 24 weeks2 mg(n=52) 4 mg
(n=52)8 mg
(n=50)ACR2063

78

73ACR5020

48

55ACR7010

28

24"These data are important because collectively they show patients experienced improvement with baricitinib as early as week two that was sustained through week 24," said Mark Genovese, M.D., the James Raitt professor of medi
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Edison Investment Research, ... the initiation of full coverage of BioAlliance ... and marketing products for orphan oncology and ... (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison has today ... merits of BioAlliance Pharma, focusing in particular ...
(Date:6/18/2013)... Toronto, Canada (PRWEB) June 18, 2013 ... FDA oversight of pharmaceutical advertising and promotion, and ... , Viewers will learn how to apply these ... enforcement examples:, ,     The fundamentals on ... advertising and promotional labeling ,     Assessing traditional ...
(Date:6/18/2013)... , June 18, 2013 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/cmbgcv/north_american ) has announced the ... Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market ... Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] ... 2017" report to their offering. ...
(Date:6/18/2013)... June 18, 2013 Earlier this year, Google ... platform. As this directly impacts the core component of ... one of the most sweeping updates since its inception in ... Technologies recently posted a very informative article on ... ‘must-have’ upgrade date for enhanced campaigns . Only ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 2Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 3
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... today announced that it has received clearance ... to begin marketing additional,diameters of its Quill(TM) ... The Quill(TM) SRS PDO is a longer-lasting ...
... fraught with,flare-ups of pain, or breakthrough pain, may ... new easy-to-use oral drug delivery system developed by,BioDelivery ... Cancer patients frequently experience two types of pain: ... continuous pain,present for long periods of time, and ...
... the Fourth ... Quarter, FRAZER, ... a 12-week, Phase 3 clinical,trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in ... The study achieved statistical significance on the primary,endpoint. Results across the 12 ...
Cached Biology Technology:Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 2Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 3Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 4Novel Technology Breaks Through Cancer Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5
(Date:6/18/2013)... Research Council, Laboratory of Molecular Biology, has been ... Young Investigator Award. Torrent is being recognized for ... algorithm to predict antimicrobial regions in proteins. Luis ... now applying this algorithm to interrogate full genomes ... with very appealing results." , Torrent obtained ...
(Date:6/18/2013)... The herbal extract of a yellow-flowered mountain plant long ... lifespan of fruit fly populations by an average of ... it,s how Rhodiola rosea , also ... attention of study leaders Mahtab Jafari and Sam Schriner. ... manner completely unrelated to dietary restriction and affects different ...
(Date:6/18/2013)... shows that weight gain and increased head size in the first ... at early school age. , The study was led by University ... 13,800 children who were born full-term. , The results, published in ... put on 40% of their birthweight in the first four weeks ... six years of age, compared with babies who only put on ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2IQ link to baby's weight gain in first month 2
... announce 7.5 million of funding for a series of projects ... H1N1 2009 or ,swine flu,. The research will look ... pig and human populations, and in hospital intensive care units. ... reported in Mexico in March this year. In June, as ...
... researchers from Carnegie Mellon University, Goettingen Medical School in ... Kingdom have received a Human Frontiers Science Program (HFSP) ... better understand the "cellular GPS" system that guides neurons ... In the course of the development and repair of ...
... CORVALLIS, Ore. - Penguins that died 44,000 years ago ... challenge the accuracy of traditional genetic aging measurements, and ... of many specimens by 200 to 600 percent. ... DNA testing to be 100,000 years old may actually ...
Cached Biology News:£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 2£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 3£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 4Carnegie Mellon researchers to develop probes to study cellular GPS 2Ancient penguin DNA raises doubts about accuracy of genetic dating techniques 2
... with a modular approach to instrument control, ... Plus NDS family provides modular software components ... management, giving you the flexibility to choose ... now and that can grow as your ...
... Workgroup solution is a highly scalable ... expression data in a workgroup or ... in over 40 leading pharmaceutical, biotechnology, ... GeneSpring Workgroup streamlines genomics research at ...
... designed for proteomic scale kinase profiling, ... and drug discovery research built on ... on-chip synthesis platform. These microarrays are ... Protein Kinase Substrate - Peptide Microarray ...
... 18 amino acid synthetic peptide whose sequences are derived from mouse ... carboxy terminus): S(21) - S - M - P - L ... A - I - D - K - K - I ... peptide may be used for neutralization and control experiments with the ...
Biology Products: